This book dives into the forefront of stem cell research, uncovering the tremendous potential of stem cell technology for neural regeneration. This comprehensive volume offers valuable insights into diverse strategies for using stem cells to study neurodegenerative and neurodevelopmental disorders, as well as advances in research of neural regeneration strategies.
Advances in Using Stem Cells to Treat Neural Diseases includes a collection of chapters carefully curated by leading experts in the field. These chapters explore the progress made in stem cell research and highlight recent advances in cell reprogramming and tissue engineering to develop disease modeling and regenerative therapy for the study and treat neural disorders. This book offers an unparalleled snapshot of the current landscape of stem cell research and an overview of up-and-coming technologies that could revolutionize the field. This unique resource would provide an important reference for stem cell biologists, neuroscientists, tissue engineers, molecular biologists, as well as students, academics and clinicans with an interest in neural regeneration
Preface.- Editorial.- Disease modeling and drug development using
patient-derived and genome-edited pluripotent stem cells.- Advances in Stem
Cell Research for MECP2-Related Disorders.- Genome editing and human induced
pluripotent stem cells facilitate Parkinson's Disease modeling.-
Orchestrating the interactions between stem cells and bioengineered
materials: treatment and modelling of neurodegenerative diseases.- Stem
cell-derived 3D models to study Alzheimers disease.-The application of
directly induced neurons to neurodegenerative disease research.-
Breakthroughs in Stem Cell-Based Treatments for ALS and FTD: Promises and
Challenges Ahead.- Retinal organoid development: disease modelling and
therapeutic strategies.- Retinal Organoid Differentiation Strategies and
Their Application in Retinal Degenerative Disease Modelling.- Cell therapy
for Parkinsons disease with pluripotent stem cells.- Drug Discovery and
Development for Neurodegenerative Diseases Using Induced Pluripotent Stem
Cells.- Cellular reprogramming to stimulate retina regeneration.
Associate Professor Raymond Wong is a Principal Investigator at the Centre for Eye Research Australia (CERA) and the Department of Ophthalmology at the University of Melbourne. He is a stem cell biologist with 20+ years of research experience, specialising in cellular reprogramming and stem cells in eye research. He completed his PhD in stem cell biology at Monash University and was awarded a California Institute of Regenerative Medicine Fellowship to pursue overseas postdoctoral training at the University of California Irvine (USA), and a Visiting Fellow Award to train at the National Institutes of Health (USA). In 2013, A/Prof Wong joined CERA with the support of a Cranborne Foundation Fellowship and a MAWA Fellowship. Hes also Founder and CSO of Mirugen - a retinal gene therapy start-up. A/Prof Wong has co-authored 95 peer-reviewed publications in the fields of stem cell and eye research. Currently his research focuses on using stem cells and gene therapy to treat retinal degeneration.
Dr. Yohei Hayashi is a unit leader at the Research and Development Center of the CiRA Foundation. He is a stem cell biologist with over 20 years of research experience, specializing in pluripotent stem cells and cellular reprogramming. He received his PhD in developmental biology from the University of Tokyo in 2009. He then worked as a postdoctoral fellow in Shinya Yamanaka's lab at the Gladstone Institute of Cardiovascular Disease (affiliated with the University of California, San Francisco), where he studied intractable diseases using patient-derived induced pluripotent stem cells (iPSCs) and the molecular mechanisms of iPSC generation. Following this, he was appointed as an assistant professor at the University of Tsukuba, a team leader at the RIKEN BioResource Research Center, and a visiting professor at the University of Tsukuba. He has published more than 50 peer-reviewed articles, including papers in Nature, Cell, and other high-impact journals, with over 5,500 citations in total. Currently, his research focuses on realizing autologous transplantation of iPSC-derived products for cell therapy and utilizing disease-specific iPSC lines for basic research and drug development.
